Northwest Biotherapeutics (NWBO) Climbs 5.38% For Past Month: Will It Surpass $1 Mark?

NWBO has never grown above $2 value even though it was on the headlines with hot cancer topics which were related to the company’s current drug developments to treat cancer having patients. This year the stock is thriving to jump off the $1 line after commencing cancer vaccine production at its Sawston, UK facility.

Everything about BSC Biotechnology: Subjects, Marks, Eligibility

On Friday session NWBO closed at $0.98 after missing only $o.02. Maybe the revenue from cancer vaccine sales will push earnings to explode by boosting the negative EPS. During the time of stocks losing at least 2%, CYDY and NWBO have started trending in searches and stock forums although they have no significant profits at all.